Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.11.4797

A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer  

Li, Yang (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.11, 2015 , pp. 4797-4800 More about this Journal
Abstract
Background: This analysis was conducted to evaluate the efficacy and safety of crizotinib based regimens in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer. Materials and Methods: Clinical studies evaluating the efficacy and safety of crizotinib based regimens on response and safety for Chinese patients with EML4-ALK positive non-small-cell lung cancer were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In crizotinib based regimens, 3 clinical studies which including 128 Chinese patients with EML4-ALK positive non-small-cell lung cancer and treated with crizotinib based regimen were considered eligible for inclusion. Pooled analysis suggested that, in all patients, the pooled RR was 59.3% (76/128) in crizotinib based regimens. ALT/AST mild visual disturbances, nausea, and vomiting were the main side effects. No treatment related death occurred in these crizotinib based treatments. Conclusions: This pooled analysis suggests that crizotinib based regimens are associated with good response rate and accepted toxicities in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer.
Keywords
crizotinib; second-line chemotherapy; EML4-ALK positive non-small-cell lung cancer;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.   DOI   ScienceOn
2 Cui S, Zhao Y, Gu A, et al (2015). Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. Med Oncol, 32, 626.
3 Ettinger DS, Akerley W, Borghaei H, et al (2012) Non-small cell lung cancer. J Natl Compr Canc Netw, 10, 1236-71.   DOI
4 Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9.   DOI   ScienceOn
5 Frampton JE (2013). Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs, 73, 2031-51.   DOI
6 Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74.   DOI
7 Gridelli C, Ciardiello F, Gallo C, et al (2012). First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol, 30, 3002-11.   DOI
8 Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.   DOI
9 Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med, 359, 1367-80.   DOI
10 Hotta K, Fujiwara Y, Kiura K, et al (2007) Relationship between response and survival in more than 50, 000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol, 2, 402-7.   DOI
11 Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
12 Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5.   DOI
13 Kanteti R, El-Hashani E, Dhanasingh I, et al (2014). Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer, 14, 185.   DOI
14 Klastersky J, Paesmans M (2001). Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer, 34, 95-101.
15 Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.   DOI
16 Leighl NB (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol, 19, 52-58.
17 Miyanaga A, Shimizu K, Noro R, et al (2013). Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer, 13, 262.   DOI   ScienceOn
18 Roberts PJ (2013). Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics, 7, 91-101.
19 National Comprehensive Cancer Network. Non Small Cell Lung Cancer. 2013, cited 2013-10-30. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
20 Rikova K, Guo A, Zeng Q, et al (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131, 1190-203.   DOI
21 Shepherd FA, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.   DOI
22 Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.   DOI
23 Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-66.   DOI
24 Steuer CE, Ramalingam SS (2014). ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options. Cancer, 120, 2392-402.   DOI
25 Weinmann M, Jeremic B, Toomes H, et al (2003). Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer, 39, 233-53.   DOI
26 Wu X, Li J (2015). Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao, 35, 753-7.
27 Cao Y, Xiao G, Qiu X, et al (2014). Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One, 9, 114008.   DOI
28 American Cancer Society (2013). Cancer Facts & Figures.
29 Berge EM, Lu X, Maxson D, et al (2013). Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer, 14, 636-43.   DOI
30 Bowles DW, Weickhardt AJ, Doebele RC, et al (2012). Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc), 48, 271-82.   DOI
31 Casaluce F, Sgambato A, Maione P, et al (2013). ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol, 8, 55-67.   DOI
32 Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9.   DOI   ScienceOn
33 Chen X, Zhou JY, Zhao J, et al (2013). Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs, 24, 1039-46.   DOI